Cloud Banner

Medical Devices

Image

North America Hereditary Cancer Testing Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Published Report
  • Nov 2022
  • North America
  • 350 Pages
  • No of Tables: 76
  • No of Figures: 43

North America Hereditary Cancer Testing  Market, By Test Type (Multi Panel Set, and Single Site Genetic Test), Diagnosis Type (Biopsy, Imaging, Lab Tests), Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray), Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Von Hippel-Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes), End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others), Distribution Channel (Direct Tender, Retail Sales), Trends and Forecast to 2029.

North America Hereditary Cancer Testing Market Analysis and Insights

Cancer is a genetic disease caused by certain mutations in the genes that control the function of cells, particularly affecting their growth and reproduction. Inherited genetic mutations are responsible for approximately 5-10% of all cancers. Researchers have linked mutations in specific genes to more than 50 hereditary cancer syndromes that affect people through the development of certain cancers. In addition, about 5-10% of breast cancer cases are associated with genetic mutations inherited from parents. Thus, the increasing prevalence of cancer is driving the steady growth of hereditary cancers and thus, driving the growth of the hereditary cancer testing market. In addition, increased demand for non-invasive testing methods and growing demand for better quality healthcare and early diagnosis are the major opportunities for the market growth. Moreover, Ethical challenges faced during hereditary cancer testing and rising competition among market players are the key challenges for the market growth.

However, stringent cancer diagnostic regulations and the high cost associated with tests may hamper the growth of the market.

Data Bridge Market Research analyzes that the North America hereditary cancer testing market is expected to reach the value of USD 5,596.19 million by 2029, at a CAGR of 13.3% during the forecast period. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2015)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Test Type (Multi Panel Set, and Single Site Genetic Test), Diagnosis Type (Biopsy, Imaging, Lab Tests), Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray), Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Von Hippel-Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes), End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others), Distribution Channel (Direct Tender, Retail Sales).

Countries Covered

U.S., Canada, Mexico

Market Players Covered

Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.

North America Hereditary Cancer Testing Market Definition

Hereditary cancer is any cancer caused by an inherited genetic mutation. Harmful variants in certain genes are associated with an increased risk of cancer. Genetic testing can estimate a person's lifetime risk of developing cancer. This can be done by looking for mutations in their genes, chromosomes, or proteins. Genetic testing is available for several types of cancer. These include breast, ovarian, colon, thyroid, prostate, pancreatic, skin cancer, sarcoma, and kidney and stomach cancer. Numerous medical studies show that 5% to 10% of common cancers are considered hereditary. Genetic tests are performed to determine whether a person carries a harmful genetic variant. These tests also help determine if a family member who has not yet had cancer has inherited the same variant as a family member known to have a cancer susceptibility alternative.

North America Hereditary Cancer Testing Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • Rising Incidence of Hereditary Cancer

Cancer arises from the uncontrolled growth of cells. Cancer is caused by harmful changes (mutations) in genetic messages (genes) that control the growth and division of cells, preventing them from doing their job effectively.

In hereditary cancer cases, the individual inherits a copy of the mutated growth regulatory gene from one parent and a working copy of the same gene from the other parent. The mutated gene is also called a "cancer susceptibility gene." As this cancer-susceptibility gene is inherited, it is found in every cell in the body, but a working copy of the gene keeps each cell functioning properly. However, if a mutation damages a functional copy of a gene in a cell, the cell can lose control of its growth and become cancerous. Thus, individuals who inherit a cancer gene are much more likely to develop certain cancers during their lifetime.

Thus, rising incidences of hereditary cancer increase the demand for hereditary cancer testing and may act as a driver for the growth of the North America hereditary cancer testing market.

  •  Increase In The Geriatric Population

Cancer can be a disease of aging patients. Across the globe, the geriatric population is increasing. The risk of hereditary cancer among geriatrics is much more. The rising geriatric population can result in better provision of the North America hereditary cancer testing market. It anticipated an upsurge in demand in the North America hereditary cancer testing market. An aging population is causing a redistribution of the demographic structure that will affect the future of health care. Undoubtedly, the risk of cancer increases exponentially with age.

Hereditary cancer, including its incidence and associated risk, using the world's largest complete family structure and medically confirmed cancer database, was approximately twice as high in the population aged 8-20 years born to affected parents or siblings of people who have no relatives. The risk of small bowel, testicular, thyroid, and bone cancers was five to eight times greater.

Thus, the increase in cancer incidences among the geriatric population is expected to be a driving factor for the growth of the North America hereditary cancer testing market.

Restraint

  • High Cost of Hereditary Cancer Testing

Hereditary cancer testing employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing player. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Testing kits are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation, and expensive medications.

In addition, testing procedures have also been used in cancer testing. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.

Thus, the high cost of cancer testing using advanced modalities and technology products may be a major restraining factor for the growth of the North America hereditary cancer testing market.

Opportunity

  • Strategic Initiatives By Market Players

The rise in the North America hereditary cancer testing market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The surge in demand for hereditary cancer treatment is significantly increasing the demand for diagnostic testing methods. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.

These strategic initiatives, such as product launches, agreements, and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the North America hereditary cancer testing market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players are expected to act as an opportunity for growth in the North America hereditary cancer testing market.

Challenge

  • Ethical Challenges Faced During Hereditary Cancer Testing

During hereditary cancer genetic testing, one of the significant ethical hindrances is health professionals' lack of basic knowledge about genetic testing and their lack of confidence in interpreting familial disease patterns. The challenge for healthcare providers is to provide sufficient information to support patient decision making-and evidence to support the reasoning behind any suggestions they might make.

The lack of reimbursement creates economic barriers to care. The process of hereditary cancer risk assessment and counseling is time-consuming, and it is unclear how best to document and bill for this service. Oncologists are often forced to navigate a potentially uncertain reimbursement environment for genetic testing, with various reimbursement policies among third-party payers.

Genetic testing for hereditary cancer elevates ethical matters, which can't be resolved with patients or their family members. The various aspects of ethical, cultural, and religious nature should not be a barrier to the act of hereditary cancer testing. All of these are issues to be solved. Therefore, ethical challenges during hereditary cancer testing are expected to challenge the market growth.

Post-COVID-19 Impact on North America Hereditary Cancer Testing Market

Many industries around the world have been disadvantaged over the past 18 months. This could be due to the major disruptions that their industrial and supply chain processes are experiencing due to various precautionary measures such as shutdowns and other restrictions that the facilities around the world have been following. The same places the North America hereditary cancer testing market. Also, consumption demand has subsequently decreased as people now have more opportunities to exclude non-essential expenses from their budgets as most people's overall finances have been severely affected by the boom. These aforementioned factors can be expected to burden the revenue margin of the North America hereditary cancer testing market during the forecast period.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the transplant diagnostics market.

Recent Development

  • In July 2022, Helio Genomics and its business partner, Fulgent Genetics (FLGT) has announced that the American Medical Association (AMA)  issued a new Category I Current Procedural Terminology (CPT) Proprietary Laboratory Analyses code for HelioLiver and broader adoption of advanced innovative surveillance tests for liver cancer in the U.S. This has helped the company to expand their product portfolio.

North America Hereditary Cancer Testing Market Scope

North America hereditary cancer testing market is segmented into test type, diagnosis type, technology, disease type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY TEST TYPE

  • MULTI PANEL TEST
  • SINGLE SITE GENETIC TEST

On the basis of test type, the North America hereditary cancer testing market is segmented into multi panel test and single site genetic test.

BY DIAGNOSIS TYPE

  • BIOPSY
  • IMAGING
  • LAB TESTS

On the basis of diagnosis type, the North America hereditary cancer testing market is segmented into biopsy, imaging, and lab tests.

BY TECHNOLOGY

  • SEQUENCING
  • POLYMERASE CHAIN REACTION (PCR)
  • MICROARRAY

On the basis of technology, the North America hereditary cancer testing market is segmented into sequencing, polymerase chain reaction (PCR), and microarray.

BY DISEASE TYPE

  • HEREDITARY BREAST & OVARIAN CANCER SYNDROME
  • COWDEN SYNDROME
  • LYNCH SYNDROME
  • HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROMES
  • FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
  • LI-FRAUMENI SYNDROME
  • VON HIPPEL-LINDAU DISEASE
  • MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROMES

On the basis of disease type, the North America hereditary cancer testing market is segmented into hereditary breast & ovarian cancer syndrome, cowden syndrome, lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), li-fraumeni syndrome, vol-hippel lindau disease, multiple endocrine neoplasias (MEN) syndrome.

BY END USER

On the basis of end user, the North America hereditary cancer testing market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others.

BY DISTRIBUTION CHANNEL

  • DIRECT TENDER
  • RETAIL SALES

On the basis of distribution channel, the North America hereditary cancer testing market is segmented into direct tender, retail sales.

North America Hereditary Cancer Testing Market Regional Analysis/Insights

The North America hereditary cancer testing market is analyzed and market size information is provided test type, diagnosis type, technology, disease type, end user, and distribution channel.

The countries covered in this market report U.S., Canada and Mexico.

  • In 2022, U.S. is dominating due to the presence of key market players in the largest consumer market with high GDP and due to its latest advanced technology and inventions for the diagnosis of cancer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Hereditary Cancer Testing Market Share Analysis

North America hereditary cancer testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America hereditary cancer testing market.

Some of the major players operating in the North America hereditary cancer testing market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.

Research Methodology: North America Hereditary Cancer Testing Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, North America vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

TABLE 1 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 2 NORTH AMERICA MULTI PANEL TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA SINGLE-SITE GENETIC TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA SEQUENCING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA MICROARRAY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA HEREDITARY BREAST & OVARIAN CANCER SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA COWDEN SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA LYNCH SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS (FAP) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA LI-FRAUMENI SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA VON HIPPEL-LINDAU DISEASE IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA HOSPITALS CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA CLINICS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA DIAGNOSTIC CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA RADIOLOGY CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA LABORATORIES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA OTHERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA DIRECT TENDER IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA RETAIL SALES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 44 U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 45 U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 46 U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 47 U.S. HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 48 U.S. BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 49 U.S. IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 50 U.S. LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 51 U.S. HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 52 U.S. HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 53 U.S. HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 54 U.S. HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 56 CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 57 CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 58 CANADA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 59 CANADA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 60 CANADA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 61 CANADA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 62 CANADA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 63 CANADA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 64 CANADA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 65 CANADA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 66 MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 67 MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 68 MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 69 MEXICO HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 70 MEXICO BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 71 MEXICO IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 72 MEXICO LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 73 MEXICO HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 74 MEXICO HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 75 MEXICO HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 76 MEXICO HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The North America Hereditary Cancer Testing Market is projected to grow at a CAGR of 13.3% during the forecast period by 2029.
The future market value of the North America Hereditary Cancer Testing Market is expected to reach USD 5,596.19 million by 2029.
The major players in the North America Hereditary Cancer Testing Market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.
The countries covered in the North America Hereditary Cancer Testing Market are the U.S., Canada, and Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials